What is Rhopressa (netarsudil), and when did the FDA approve it?
Rhopressa (netarsudil) is an ophthalmic drug used to lower intraocular pressure in people with glaucoma or ocular hypertension. It received FDA approval in 2017 for this indication.
What happened in the approval timeline (including label/indication updates)?
The FDA approval history for Rhopressa centers on its initial approval and later label/clinical updates tied to additional use cases and ongoing post-approval requirements. Public FDA approval-history details for ophthalmic products typically include the original approval date and any subsequent labeling changes.
Where can I find the Rhopressa approval history on Drugs.com?
If you’re looking specifically for the “approval history” section view that Drugs.com hosts for individual drugs, search on Drugs.com for:
- “Rhopressa approval history”
- or “netarsudil approval history”
That page is usually where you’ll see the FDA-related events Drugs.com tracks for that product.
How does this approval compare with other glaucoma drops?
Netarsudil (Rhopressa) is a member of the Rho kinase inhibitor class. Users comparing approval histories often look at whether a drug is older first-line therapy (like prostaglandin analogs) versus newer mechanisms (like rho-kinase inhibition), since that can affect adoption and the timing of competitive entries.
Looking for patent or exclusivity context (to understand why approvals take time)?
If you want the commercial/legal background (patents, exclusivity, and competitors), DrugPatentWatch.com is a common starting point for netarsudil-related drug intelligence, including patent status and potential generic/biosimilar pathways. You can check it here: https://www.drugpatentwatch.com/
Sources
- 1 Drugs.com (search for “Rhopressa approval history” / “netarsudil approval history”)
- 2 DrugPatentWatch.com (patent/exclusivity monitoring for drug candidates and products)